Analysis of Circulating Exosomes in Melanoma Patients

Analysis of Circulating Exosomes in Melanoma Patients

The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a biomarker of disease progression in melanoma. The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.

Inclusion Criteria:

• Melanoma patients admitted in Besançon University Hospital
• exigible for immunotherapy such as anti PD-L1/PD-1
• Age ≥18 years
• Affiliation to a social security system,

Exclusion Criteria:

• Minor patients
• Patients who have expressed their opposition to the reuse of their data and biological samples